A Phase 2 interventional study of VK2735 and Placebo in Weight Loss, sponsored by Viking Therapeutics, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-12.
Sponsored by Viking Therapeutics, Inc. · Phase 2, Interventional, and Treatment
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.
VK2735 or matched placebo will be administered once weekly.
1,223 studies on the registry are indexed under Body Weight; 131 are open to participants now.
This study's enrollment of 176 is above the median of 64 across 947 interventional studies indexed under Body Weight.
Browse Body Weight studies →Viking Therapeutics, Inc. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Placebo
Biological: Placebo
VK2735 is a peptide GLP-1 and GIP dual agonist
Biological: VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist
Biological: VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist
Biological: VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist
Biological: VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist
Placebo comparator
Percent (relative) change from baseline to Week 13 in body weight
To measure the efficacy of VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition
Time frame: 13 weeks
Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13
To measure the efficacy of VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition
Time frame: 13 weeks
Incidence of treatment-emergent adverse events (TEAEs), TESAEs, AESI
To evaluate the safety and tolerability of VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition
Time frame: 13 weeks
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Viking Therapeutics, Inc.